The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer

Systemic treatment options for patients with lung cancer have expanded in recent years, with a number of immunotherapeutic strategies now in our treatment armamentarium. Toxicity of and resistance to treatment hold a major stake in lung cancer morbidity and mortality. Herein, we summarise the backgr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bredin, Philip, Naidoo, Jarushka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388426/
https://www.ncbi.nlm.nih.gov/pubmed/35876944
http://dx.doi.org/10.1007/s10555-022-10039-1
_version_ 1784770223488892928
author Bredin, Philip
Naidoo, Jarushka
author_facet Bredin, Philip
Naidoo, Jarushka
author_sort Bredin, Philip
collection PubMed
description Systemic treatment options for patients with lung cancer have expanded in recent years, with a number of immunotherapeutic strategies now in our treatment armamentarium. Toxicity of and resistance to treatment hold a major stake in lung cancer morbidity and mortality. Herein, we summarise the background, current evidence and potential mechanisms underlying the role of the commensal gut microbiota in immunotherapy outcomes such as response and toxicity in patients with non-small cell lung cancer (NSCLC).
format Online
Article
Text
id pubmed-9388426
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-93884262022-08-20 The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer Bredin, Philip Naidoo, Jarushka Cancer Metastasis Rev Article Systemic treatment options for patients with lung cancer have expanded in recent years, with a number of immunotherapeutic strategies now in our treatment armamentarium. Toxicity of and resistance to treatment hold a major stake in lung cancer morbidity and mortality. Herein, we summarise the background, current evidence and potential mechanisms underlying the role of the commensal gut microbiota in immunotherapy outcomes such as response and toxicity in patients with non-small cell lung cancer (NSCLC). Springer US 2022-07-25 2022 /pmc/articles/PMC9388426/ /pubmed/35876944 http://dx.doi.org/10.1007/s10555-022-10039-1 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Bredin, Philip
Naidoo, Jarushka
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
title The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
title_full The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
title_fullStr The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
title_full_unstemmed The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
title_short The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
title_sort gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388426/
https://www.ncbi.nlm.nih.gov/pubmed/35876944
http://dx.doi.org/10.1007/s10555-022-10039-1
work_keys_str_mv AT bredinphilip thegutmicrobiomeimmunecheckpointinhibitionandimmunerelatedadverseeventsinnonsmallcelllungcancer
AT naidoojarushka thegutmicrobiomeimmunecheckpointinhibitionandimmunerelatedadverseeventsinnonsmallcelllungcancer
AT bredinphilip gutmicrobiomeimmunecheckpointinhibitionandimmunerelatedadverseeventsinnonsmallcelllungcancer
AT naidoojarushka gutmicrobiomeimmunecheckpointinhibitionandimmunerelatedadverseeventsinnonsmallcelllungcancer

Ejemplares similares